Clinical course and outcome of patients with hodgkin's disease who progress after autologous transplantation

Mary Varterasian, Voravit Ratanatharathorn, Joseph P. Uberti, Chatchada Karanes, Esteban Abella, Feroze Momin, Claude Sportes, Ayad Al-Katib, Lawrence Lum, Lance K. Heilbrun, Lyle L. Sensenbrenner

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Twenty-six of fifty-eight patients undergoing autologous bone marrow transplantation (autoBMT) or peripheral stem cell transplantation (PSCT) for Hodgkin's disease had progression of lymphoma (Hodgkin's or non-Hodgkin's) during the course of their follow-up. The majority of progressions, 81% (21/26), occurred within the first year of transplant; 12% (3/26) occurred at three years or more. Three patients developed a non-Hodgkin's lymphoma; all B-cell tumors primarily involving the gastrointestinal tract. The majority of patients (23/26) received at least one therapy after progression and 65% (17/26) of patients received multiple therapies. One patient who received a second BMT is alive without evidence of disease at 49 months following the second autologous BMT. The median survival for the entire group is 11 months. Forty-six percent (12/26) of patients survived more than one year and twenty-three percent (6/26) survived more than two years after disease progression. Post-progression survival is significantly related to time to progression.

Original languageEnglish (US)
Pages (from-to)59-65
Number of pages7
JournalLeukemia and Lymphoma
Volume20
Issue number1-2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Autologous Transplantation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Disease Progression
Peripheral Blood Stem Cell Transplantation
Survival
Bone Marrow Transplantation
Gastrointestinal Tract
B-Lymphocytes
Transplants
Therapeutics
Neoplasms

Keywords

  • AutoBMT
  • Hodgkin's disease
  • Progression
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Varterasian, M., Ratanatharathorn, V., Uberti, J. P., Karanes, C., Abella, E., Momin, F., ... Sensenbrenner, L. L. (1995). Clinical course and outcome of patients with hodgkin's disease who progress after autologous transplantation. Leukemia and Lymphoma, 20(1-2), 59-65. https://doi.org/10.3109/10428199509054754

Clinical course and outcome of patients with hodgkin's disease who progress after autologous transplantation. / Varterasian, Mary; Ratanatharathorn, Voravit; Uberti, Joseph P.; Karanes, Chatchada; Abella, Esteban; Momin, Feroze; Sportes, Claude; Al-Katib, Ayad; Lum, Lawrence; Heilbrun, Lance K.; Sensenbrenner, Lyle L.

In: Leukemia and Lymphoma, Vol. 20, No. 1-2, 01.01.1995, p. 59-65.

Research output: Contribution to journalArticle

Varterasian, M, Ratanatharathorn, V, Uberti, JP, Karanes, C, Abella, E, Momin, F, Sportes, C, Al-Katib, A, Lum, L, Heilbrun, LK & Sensenbrenner, LL 1995, 'Clinical course and outcome of patients with hodgkin's disease who progress after autologous transplantation', Leukemia and Lymphoma, vol. 20, no. 1-2, pp. 59-65. https://doi.org/10.3109/10428199509054754
Varterasian, Mary ; Ratanatharathorn, Voravit ; Uberti, Joseph P. ; Karanes, Chatchada ; Abella, Esteban ; Momin, Feroze ; Sportes, Claude ; Al-Katib, Ayad ; Lum, Lawrence ; Heilbrun, Lance K. ; Sensenbrenner, Lyle L. / Clinical course and outcome of patients with hodgkin's disease who progress after autologous transplantation. In: Leukemia and Lymphoma. 1995 ; Vol. 20, No. 1-2. pp. 59-65.
@article{28144883e20446af9e75dc1fcc14829d,
title = "Clinical course and outcome of patients with hodgkin's disease who progress after autologous transplantation",
abstract = "Twenty-six of fifty-eight patients undergoing autologous bone marrow transplantation (autoBMT) or peripheral stem cell transplantation (PSCT) for Hodgkin's disease had progression of lymphoma (Hodgkin's or non-Hodgkin's) during the course of their follow-up. The majority of progressions, 81{\%} (21/26), occurred within the first year of transplant; 12{\%} (3/26) occurred at three years or more. Three patients developed a non-Hodgkin's lymphoma; all B-cell tumors primarily involving the gastrointestinal tract. The majority of patients (23/26) received at least one therapy after progression and 65{\%} (17/26) of patients received multiple therapies. One patient who received a second BMT is alive without evidence of disease at 49 months following the second autologous BMT. The median survival for the entire group is 11 months. Forty-six percent (12/26) of patients survived more than one year and twenty-three percent (6/26) survived more than two years after disease progression. Post-progression survival is significantly related to time to progression.",
keywords = "AutoBMT, Hodgkin's disease, Progression, Survival",
author = "Mary Varterasian and Voravit Ratanatharathorn and Uberti, {Joseph P.} and Chatchada Karanes and Esteban Abella and Feroze Momin and Claude Sportes and Ayad Al-Katib and Lawrence Lum and Heilbrun, {Lance K.} and Sensenbrenner, {Lyle L.}",
year = "1995",
month = "1",
day = "1",
doi = "10.3109/10428199509054754",
language = "English (US)",
volume = "20",
pages = "59--65",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Clinical course and outcome of patients with hodgkin's disease who progress after autologous transplantation

AU - Varterasian, Mary

AU - Ratanatharathorn, Voravit

AU - Uberti, Joseph P.

AU - Karanes, Chatchada

AU - Abella, Esteban

AU - Momin, Feroze

AU - Sportes, Claude

AU - Al-Katib, Ayad

AU - Lum, Lawrence

AU - Heilbrun, Lance K.

AU - Sensenbrenner, Lyle L.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Twenty-six of fifty-eight patients undergoing autologous bone marrow transplantation (autoBMT) or peripheral stem cell transplantation (PSCT) for Hodgkin's disease had progression of lymphoma (Hodgkin's or non-Hodgkin's) during the course of their follow-up. The majority of progressions, 81% (21/26), occurred within the first year of transplant; 12% (3/26) occurred at three years or more. Three patients developed a non-Hodgkin's lymphoma; all B-cell tumors primarily involving the gastrointestinal tract. The majority of patients (23/26) received at least one therapy after progression and 65% (17/26) of patients received multiple therapies. One patient who received a second BMT is alive without evidence of disease at 49 months following the second autologous BMT. The median survival for the entire group is 11 months. Forty-six percent (12/26) of patients survived more than one year and twenty-three percent (6/26) survived more than two years after disease progression. Post-progression survival is significantly related to time to progression.

AB - Twenty-six of fifty-eight patients undergoing autologous bone marrow transplantation (autoBMT) or peripheral stem cell transplantation (PSCT) for Hodgkin's disease had progression of lymphoma (Hodgkin's or non-Hodgkin's) during the course of their follow-up. The majority of progressions, 81% (21/26), occurred within the first year of transplant; 12% (3/26) occurred at three years or more. Three patients developed a non-Hodgkin's lymphoma; all B-cell tumors primarily involving the gastrointestinal tract. The majority of patients (23/26) received at least one therapy after progression and 65% (17/26) of patients received multiple therapies. One patient who received a second BMT is alive without evidence of disease at 49 months following the second autologous BMT. The median survival for the entire group is 11 months. Forty-six percent (12/26) of patients survived more than one year and twenty-three percent (6/26) survived more than two years after disease progression. Post-progression survival is significantly related to time to progression.

KW - AutoBMT

KW - Hodgkin's disease

KW - Progression

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0029592119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029592119&partnerID=8YFLogxK

U2 - 10.3109/10428199509054754

DO - 10.3109/10428199509054754

M3 - Article

C2 - 8750624

AN - SCOPUS:0029592119

VL - 20

SP - 59

EP - 65

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -